Brainsway Stock Working Capital
| BRSYF Stock | USD 3.15 0.00 0.00% |
BrainsWay fundamentals help investors to digest information that contributes to BrainsWay's financial success or failures. It also enables traders to predict the movement of BrainsWay Pink Sheet. The fundamental analysis module provides a way to measure BrainsWay's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BrainsWay pink sheet.
BrainsWay |
BrainsWay Company Working Capital Analysis
BrainsWay's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current BrainsWay Working Capital | 10 M |
Most of BrainsWay's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BrainsWay is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
In accordance with the company's disclosures, BrainsWay has a Working Capital of 10 M. This is 97.65% lower than that of the Healthcare sector and 99.27% lower than that of the Medical Devices industry. The working capital for all United States stocks is 99.32% higher than that of the company.
BrainsWay Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BrainsWay's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of BrainsWay could also be used in its relative valuation, which is a method of valuing BrainsWay by comparing valuation metrics of similar companies.BrainsWay is currently under evaluation in working capital category among its peers.
BrainsWay Fundamentals
| Return On Equity | -0.2 | |||
| Return On Asset | -0.0751 | |||
| Profit Margin | (0.37) % | |||
| Operating Margin | (0.29) % | |||
| Current Valuation | (24.98 M) | |||
| Shares Outstanding | 33.08 M | |||
| Shares Owned By Insiders | 19.83 % | |||
| Shares Owned By Institutions | 1.11 % | |||
| Price To Earning | (23.91) X | |||
| Price To Book | 0.61 X | |||
| Price To Sales | 1.11 X | |||
| Revenue | 29.66 M | |||
| Gross Profit | 24.35 M | |||
| EBITDA | (3.31 M) | |||
| Net Income | (6.46 M) | |||
| Cash And Equivalents | 52.45 M | |||
| Cash Per Share | 1.50 X | |||
| Total Debt | 754 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 7.71 X | |||
| Book Value Per Share | 1.46 X | |||
| Cash Flow From Operations | 884 K | |||
| Earnings Per Share | (0.22) X | |||
| Target Price | 10.75 | |||
| Number Of Employees | 118 | |||
| Beta | 0.2 | |||
| Market Capitalization | 35.72 M | |||
| Total Asset | 75.73 M | |||
| Retained Earnings | (47 M) | |||
| Working Capital | 10 M | |||
| Current Asset | 14 M | |||
| Current Liabilities | 4 M | |||
| Z Score | 28.2 | |||
| Net Asset | 75.73 M |
About BrainsWay Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BrainsWay's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BrainsWay using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BrainsWay based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in BrainsWay Pink Sheet
When determining whether BrainsWay offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BrainsWay's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainsway Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainsway Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BrainsWay. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in BrainsWay Pink Sheet please use our How to Invest in BrainsWay guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.